HIV-1 persists lifelong in memory cells of the immune system as latent provirus that rebounds upon treatment interruption. Therefore, the latent reservoir is the main target for an HIV cure. Here, we studied the direct link between integration site and transcription using LEDGINs and Barcoded HIV-ensembles (B-HIVE). LEDGINs are antivirals that inhibit the interaction between HIV-1 integrase and the chromatin-tethering factor LEDGF/p75. They were used as a tool to retarget integration, while the effect on HIV expression was measured with B-HIVE. B-HIVE tracks insert-specific HIV expression by tagging a unique barcode in the HIV genome. We confirmed that LEDGINs retarget integration out of gene-dense and actively transcribed regions. The distance to H3K36me3, the marker recognized by LEDGF/p75, clearly increased. LEDGIN treatment reduced viral RNA expression and increased the proportion of silent provirus. Finally, silent proviruses obtained after LEDGIN treatment were located further away from epigenetic marks associated with active transcription. Interestingly, proximity to enhancers stimulated transcription irrespective of LEDGIN treatment, while the distance to H3K36me3 only changed after treatment with LEDGINs. The fact that proximity to these markers are associated with RNA expression support the direct link between provirus integration site and viral expression.

Center for Genomic Regulation The Barcelona Institute of Science and Technology Barcelona Catalunya Spain

Institute of Molecular Genetics Czech Academy of Sciences Videnska Prague Czech Republic

Laboratory for Molecular Virology and Gene Therapy Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Flanders Belgium

University Pompeu Fabra Barcelona Catalunya Spain

Zobrazit více v PubMed

Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R. et al. .. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295–1300. PubMed

Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C. et al. .. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999; 5:512. PubMed

Chomont N., El-Far M., Ancuta P., Trautmann L., Procopio F.A., Yassine-Diab B., Boucher G., Boulassel M.-R., Ghattas G., Brenchley J.M. et al. .. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 2009; 15:893. PubMed PMC

Chun T.-W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A.M., Baseler M., Lloyd A.L., Nowak M.A., Fauci A.S.. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 1997; 94:13193–13197. PubMed PMC

Chun T.-W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C. et al. .. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997; 387:183–188. PubMed

Deeks S.G., Lewin S.R., Ross A.L., Ananworanich J., Benkirane M., Cannon P., Chomont N., Douek D., Lifson J.D., Lo Y.-R. et al. .. International AIDS society global scientific strategy: towards an HIV cure 2016. Nat. Med. 2016; 22:839. PubMed PMC

Darcis G., Van Driessche B., Van Lint C.. HIV latency: should we shock or lock?. Trends Immunol. 2017; 38:217–228. PubMed

Nguyen K., Das B., Dobrowolski C., Karn J.. Multiple histone lysine methyltransferases are required for the establishment and maintenance of HIV-1 latency. MBio. 2017; 8:e00133-17. PubMed PMC

Gallastegui E., Millán-Zambrano G., Terme J.-M., Chávez S., Jordan A.. Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J. Virol. 2011; 85:3187–3202. PubMed PMC

Pearson R., Kim Y.K., Hokello J., Lassen K., Friedman J., Tyagi M., Karn J.. Epigenetic silencing of Human Immunodeficiency Virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J. Virol. 2008; 82:12291–12303. PubMed PMC

Matsuda Y., Kobayashi-Ishihara M., Fujikawa D., Ishida T., Watanabe T., Yamagishi M.. Epigenetic heterogeneity in HIV-1 latency establishment. Sci. Rep. 2015; 5:7701. PubMed PMC

Tyagi M., Pearson R.J., Karn J.. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 2010; 84:6425–6437. PubMed PMC

Battivelli E., Dahabieh M.S., Abdel-Mohsen M., Svensson J.P., Tojal Da Silva I., Cohn L.B., Gramatica A., Deeks S., Greene W.C., Pillai S.K. et al. .. Chromatin functional states correlate with HIV latency reversal in infected primary CD4+ T cells. Elife. 2018; 7:e34655. PubMed PMC

Trejbalová K., Kovářová D., Blažková J., Machala L., Jilich D., Weber J., Kučerová D., Vencálek O., Hirsch I., Hejnar J.. Development of 5′ LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals. Clin. Epigenet. 2016; 8:19. PubMed PMC

Blazkova J., Trejbalova K., Gondois-Rey F., Halfon P., Philibert P., Guiguen A., Verdin E., Olive D., Van Lint C., Hejnar J. et al. .. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 2009; 5:e1000554. PubMed PMC

Jordan A., Defechereux P., Verdin E.. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 2001; 20:1726–1738. PubMed PMC

Lewinski M.K., Bisgrove D., Shinn P., Chen H., Hoffmann C., Hannenhalli S., Verdin E., Berry C.C., Ecker J.R., Bushman F.D.. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 2005; 79:6610–6619. PubMed PMC

Brady T., Agosto L.M., Malani N., Berry C.C., O’Doherty U., Bushman F.. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS. 2009; 23:1461–1471. PubMed PMC

Han Y., Lin Y.B., An W., Xu J., Yang H.-C., O’Connell K., Dordai D., Boeke J.D., Siliciano J.D., Siliciano R.F.. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional read through. Cell Host Microbe. 2008; 4:134–146. PubMed PMC

Shan L., Yang H.C., Rabi S.A., Bravo H.C., Shroff N.S., Irizarry R.A.. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J. Virol. 2011; 85:5384–5393. PubMed PMC

Einkauf K.B., Lee G.Q., Gao C., Sharaf R., Sun X., Hua S., Chen S.M. Y., Jiang C., Lian X., Chowdhury F.Z. et al. .. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J. Clin. Invest. 2019; 129:988–998. PubMed PMC

Cherepanov P., Maertens G., Proost P., Devreese B., Van Beeumen J., Engelborghs Y., De Clercq E., Debyser Z.. HIV-1 integrase forms stable tetramers and associates with LEDGF/P75 protein in human cells. J. Biol. Chem. 2003; 278:372–381. PubMed

Lesbats P., Engelman A.N., Cherepanov P. Retroviral DNA integration. Chem. Rev. 2016; 116:12730–12757. PubMed PMC

Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., Bushman F.. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002; 110:521–529. PubMed

Shun M.-C., Raghavendra N.K., Vandegraaff N., Daigle J.E., Hughes S., Kellam P., Cherepanov P., Engelman A.. LEDGF/P75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 2007; 21:1767–1778. PubMed PMC

Cherepanov P., Ambrosio A.L.B., Rahman S., Ellenberger T., Engelman A.. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator P75. Proc. Natl. Acad. Sci. U.S.A. 2005; 102:17308–17313. PubMed PMC

Eidahl J.O., Crowe B.L., North J.A., McKee C.J., Shkriabai N., Feng L., Plumb M., Graham R.L., Gorelick R.J., Hess S. et al. .. Structural basis for high-affinity binding of LEDGF PWWP to mononucleosomes. Nucleic Acids Res. 2013; 41:3924–3936. PubMed PMC

Pradeepa M.M., Sutherland H.G., Ule J., Grimes G.R., Bickmore W.A.. Psip1/Ledgf P52 binds methylated histone H3K36 and splicing factors and contributes to the regulation of alternative splicing. PLoS Genet. 2012; 8:e1002717. PubMed PMC

van Nuland R., van Schaik F.M., Simonis M., van Heesch S., Cuppen E., Boelens R., Timmers H.M., van Ingen H.. Nucleosomal DNA binding drives the recognition of H3K36-methylated nucleosomes by the PSIP1-PWWP domain. Epigenet. Chromatin. 2013; 6:12. PubMed PMC

Ciuffi A., Llano M., Poeschla E., Hoffmann C., Leipzig J., Shinn P., Ecker J.R., Bushman F.. A role for LEDGF/P75 in targeting HIV DNA integration. Nat. Med. 2005; 11:1287. PubMed

Vranckx L.S., Demeulemeester J., Saleh S., Boll A., Vansant G., Schrijvers R., Weydert C., Battivelli E., Verdin E., Cereseto A. et al. .. LEDGIN-mediated inhibition of Integrase–LEDGF/P75 interaction reduces reactivation of residual latent HIV. EBioMedicine. 2016; 8:248–264. PubMed PMC

Christ F., Voet A., Marchand A., Nicolet S., Desimmie B.A., Marchand D., Bardiot D., Van der Veken N.J., Van Remoortel B., Strelkov S.V. et al. .. Rational design of Small-molecule inhibitors of the LEDGF/P75-integrase interaction and HIV replication. Nat. Chem. Biol. 2010; 6:442–448. PubMed

Christ F., Shaw S., Demeulemeester J., Desimmie B.A., Marchand A., Butler S., Smets W., Chaltin P., Westby M., Debyser Z. et al. .. Small-molecule inhibitors of the LEDGF/P75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob. Agents Chemother. 2012; 56:4365–4374. PubMed PMC

Demeulemeester J., Chaltin P., Marchand A., De Maeyer M., Debyser Z., Christ F.. LEDGINs, non-catalytic site inhibitors of HIV-1 Integrase: a patent review (2006 – 2014). Expert Opin. Ther. Pat. 2014; 24:609–632. PubMed

Al-Mawsawi L.Q., Neamati N.. Allosteric inhibitor development targeting HIV-1 integrase. ChemMedChem. 2011; 6:228–241. PubMed PMC

Tsiang M., Jones G.S., Niedziela-Majka A., Kan E., Lansdon E.B., Huang W., Hung M., Samuel D., Novikov N., Xu Y. et al. .. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J. Biol. Chem. 2012; 287:21189–21203. PubMed PMC

Kessl J.J., Jena N., Koh Y., Taskent-Sezgin H., Slaughter A., Feng L., de Silva S., Wu L., Le Grice S.F.J., Engelman A. et al. .. Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J. Biol. Chem. 2012; 287:16801–16811. PubMed PMC

Cherepanov P., Sun Z.-Y.J., Rahman S., Maertens G., Wagner G., Engelman A.. Solution structure of the HIV-1 integrase-binding domain in LEDGF/P75. Nat. Struct. Mol. Biol. 2005; 12:526. PubMed

Desimmie B.A., Schrijvers R., Demeulemeester J., Borrenberghs D., Weydert C., Thys W., Vets S., Van Remoortel B., Hofkens J., De Rijck J. et al. .. LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology. 2013; 10:57. PubMed PMC

Jurado K.A., Wang H., Slaughter A., Feng L., Kessl J.J., Koh Y., Wang W., Ballandras-Colas A., Patel P.A., Fuchs J.R. et al. .. Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc. Natl. Acad. Sci. U.S.A. 2013; 110:8690–8695. PubMed PMC

Balakrishnan M., Yant S.R., Tsai L., O’Sullivan C., Bam R.A., Tsai A., Niedziela-Majka A., Stray K.M., Sakowicz R., Cihlar T.. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One. 2013; 8:e74163. PubMed PMC

Le Rouzic E., Bonnard D., Chasset S., Bruneau J.-M., Chevreuil F., Le Strat F., Nguyen J., Beauvoir R., Amadori C., Brias J. et al. .. Dual inhibition of HIV-1 replication by Integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. Retrovirology. 2013; 10:144. PubMed PMC

Chen H.-C., Martinez J.P., Zorita E., Meyerhans A., Filion G.J. Position effects influence HIV latency reversal. Nat. Struct. Mol. Biol. 2017; 24:47–54. PubMed

Miklík D., Šenigl F., Hejnar J.. Proviruses with long-term stable expression accumulate in transcriptionally active chromatin close to the gene regulatory elements: comparison of ASLV-, HIV- and MLV-derived VECTORS. Viruses. 2018; 10:116. PubMed PMC

Chen H.-C., Zorita E., Filion G.J.. Using barcoded HIV ensembles (B-HIVE) for single provirus transcriptomics. Curr. Protoc. Mol. Biol. 2018; 122:e56. PubMed

Ablashi D.V, Berneman Z.N., Kramarsky B., Whitman J., Asano Y., Pearson G.R.. Human Herpesvirus-7 (HHV-7): current status. Clin. Diagn. Virol. 1995; 4:1–13. PubMed

Vincent-Lacaze N., Snyder R.O., Gluzman R., Bohl D., Lagarde C., Danos O.. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J. Virol. 1999; 73:1949–1955. PubMed PMC

Vansant G., Vranckx L.S., Zurnic I., Van Looveren D., Van de Velde P., Nobles C., Gijsbers R., Christ F., Debyser Z.. Impact of LEDGIN treatment during virus production on residual HIV-1 transcription. Retrovirology. 2019; 16:8. PubMed PMC

Zhang L., Lewin S.R., Markowitz M., Lin H.H., Skulsky E., Karanicolas R.. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J. Exp. Med. 1999; 190:725–732. PubMed PMC

Yu G., Wang L.-G., Han Y., He Q.-Y.. ClusterProfiler: an R package for comparing biological themes among gene clusters. Omi. A J. Integr. Biol. 2012; 16:284–287. PubMed PMC

Rosenthal R., Rubin D.B.. Ensemble-adjusted P values. Psychol. Bull. 1983; 94:540–541.

Wright S.P. Adjusted P-values for simultaneous inference. Biometrics. 1992; 48:1005–1013.

Benjamini Y., Hochberg Y.. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B. 1995; 57:289–300.

Cuscó P., Filion G.J.. Zerone: a ChIP-Seq discretizer for multiple replicates with built-in quality control. Bioinformatics. 2016; 32:2896–2902. PubMed PMC

Bray N.L., Pimentel H., Melsted P., Pachter L. Near-optimal probabilistic RNA-Seq quantification. Nat. Biotechnol. 2016; 34:525–527. PubMed

Reeder J.E., Kwak Y.-T., McNamara R.P., Forst C.V., D’Orso I.. HIV Tat controls RNA polymerase II and the epigenetic landscape to transcriptionally reprogram target immune cells. Elife. 2015; 4:e08955. PubMed PMC

Orlando D.A., Chen M.W., Brown V.E., Solanki S., Choi Y.J., Olson E.R., Fritz C.C., Bradner J.E., Guenther M.G.. Quantitative ChIP-Seq normalization reveals global modulation of the epigenome. Cell Rep. 2014; 9:1163–1170. PubMed

Mansour M.R., Abraham B.J., Anders L., Berezovskaya A., Gutierrez A., Durbin A.D., Etchin J., Lawton L., Sallan S.E., Silverman L.B. et al. .. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014; 346:1373–1377. PubMed PMC

Hollenhorst P.C., Chandler K.J., Poulsen R.L., Johnson W.E., Speck N.A., Graves B.J.. DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet. 2009; 5:e1000778. PubMed PMC

Wang G.P., Ciuffi A., Leipzig J., Berry C.C., Bushman F.D. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 2007; 17:1186–1194. PubMed PMC

Kanehisa M., Goto S.. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28:27–30. PubMed PMC

Kanehisa M., Sato Y., Furumichi M., Morishima K., Tanabe M.. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2018; 47:D590–D595. PubMed PMC

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019; 28:1947–1951. PubMed PMC

Bannister A.J., Schneider R., Myers F.A., Thorne A.W., Crane-Robinson C., Kouzarides T.. Spatial distribution of Di- and Tri-Methyl lysine 36 of histone H3 at active genes. J. Biol. Chem. 2005; 280:17732–17736. PubMed

Wu H., Zeng H., Lam R., Tempel W., Amaya M.F., Xu C., Dombrovski L., Qiu W., Wang Y., Min J.. Structural and histone binding ability characterizations of human PWWP domains. PLoS One. 2011; 6:e18919. PubMed PMC

Schrijvers R., Vets S., De Rijck J., Malani N., Bushman F.D., Debyser Z., Gijsbers R.. HRP-2 determines HIV-1 integration site selection in LEDGF/P75 depleted cells. Retrovirology. 2012; 9:84. PubMed PMC

Schrijvers R., De Rijck J., Demeulemeester J., Adachi N., Vets S., Ronen K., Christ F., Bushman F.D., Debyser Z., Gijsbers R.. LEDGF/P75-Independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog. 2012; 8:e1002558. PubMed PMC

Zentner G.E., Tesar P.J., Scacheri P.C.. Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res. 2011; 21:1273–1283. PubMed PMC

Mellor J., Dudek P., Clynes D.. A glimpse into the epigenetic landscape of gene regulation. Curr. Opin. Genet. Dev. 2008; 18:116–122. PubMed

Pott S., Lieb J.D.. What are super-enhancers?. Nat. Genet. 2014; 47:8. PubMed

Delannoy A., Poirier M., Bell B. Cat and Mouse: HIV transcription in latency, immune evasion and cure/remission strategies. Viruses. 2019; 11:269. PubMed PMC

Schwartz C., Bouchat S., Marban C., Gautier V., Van Lint C., Rohr O., Le Douce V.. On the way to find a cure: purging latent HIV-1 reservoirs. Biochem. Pharmacol. 2017; 146:10–22. PubMed

Kim Y., Anderson J.L., Lewin S.R.. Getting the “Kill” into “Shock and Kill”: Strategies to eliminate latent HIV. Cell Host Microbe. 2018; 23:14–26. PubMed PMC

Abner E., Jordan A.. HIV “Shock and Kill” therapy: in need of revision. Antiviral Res. 2019; 166:19–34. PubMed

Bullen C.K., Laird G.M., Durand C.M., Siliciano J.D., Siliciano R.F.. Novel Ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 2014; 20:425–429. PubMed PMC

Ho Y.C., Shan L., Hosmane N.N., Wang J., Laskey S.B., Rosenbloom D.I.. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013; 155:540–551. PubMed PMC

Mousseau G., Mediouni S., Valente S.T.. Targeting HIV transcription: the quest for a functional cure. Curr. Top. Microbiol. Immunol. 2015; 389:121–145. PubMed PMC

Mousseau G., Kessing C.F., Fromentin R., Trautmann L., Chomont N., Valente S.T.. The tat inhibitor didehydro-cortistatin a prevents HIV-1 reactivation from latency. MBio. 2015; 6:e00465-15. PubMed PMC

Kessing C.F., Nixon C.C., Li C., Tsai P.M., Takata H., Mousseau G., Ho P.T., Honeycutt J.B., Fallahi M., Trautmann L. et al. .. In vivo suppression of HIV rebound by didehydro-cortistatin A, a “Block-and-Lock” strategy for HIV-1 cure. Cell Rep. 2017; 21:600–611. PubMed PMC

Debyser Z., Vansant G., Bruggemans A., Janssens J., Christ F.. Insight in HIV integration site selection provides a block-and-lock strategy for a functional cure of HIV infection. Viruses. 2018; 11:12. PubMed PMC

Wang Z., Zang C., Rosenfeld J.A., Schones D.E., Barski A., Cuddapah S., Cui K., Roh T.-Y., Peng W., Zhang M.Q. et al. .. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat. Genet. 2008; 40:897–903. PubMed PMC

Huff J.T., Plocik A.M., Guthrie C., Yamamoto K.R.. Reciprocal intronic and exonic histone modification regions in humans. Nat. Struct. Mol. Biol. 2010; 17:1495. PubMed PMC

Farooq Z., Banday S., Pandita T.K., Altaf M.. The many faces of histone H3K79 methylation. Mutat. Res. Rev. Mutat. Res. 2016; 768:46–52. PubMed PMC

Creyghton M.P., Cheng A.W., Welstead G.G., Kooistra T., Carey B.W., Steine E.J., Hanna J., Lodato M.A., Frampton G.M., Sharp P.A. et al. .. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. U.S.A. 2010; 107:21931–21936. PubMed PMC

Lee K., Ambrose Z., Martin T.D., Oztop I., Mulky A., Julias J.G., Vandegraaff N., Baumann J.G., Wang R., Yuen W. et al. .. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe. 2010; 7:221–233. PubMed PMC

Demeulemeester J., De Rijck J., Gijsbers R., Debyser Z.. Retroviral integration: site matters: mechanisms and consequences of retroviral integration site selection. Bioessays. 2015; 37:1202–1214. PubMed PMC

Wong R.W., Mamede J.I., Hope T.J.. Impact of nucleoporin-mediated chromatin localization and nuclear architecture on HIV integration site selection. J. Virol. 2015; 89:9702–9705. PubMed PMC

Lusic M., Siliciano R.F.. Nuclear landscape of HIV-1 infection and integration. Nat. Rev. Microbiol. 2016; 15:69. PubMed

Burdick R.C., Hu W.-S., Pathak V.K.. Nuclear import of APOBEC3F-Labeled HIV-1 preintegration complexes. Proc. Natl. Acad. Sci. U.S.A. 2013; 110:E4780–E4789. PubMed PMC

Di Primio C., Quercioli V., Allouch A., Gijsbers R., Christ F., Debyser Z., Arosio D., Cereseto A.. Single-cell imaging of HIV-1 provirus (SCIP). Proc. Natl. Acad. Sci. U.S.A. 2013; 110:5636–5641. PubMed PMC

Marini B., Kertesz-Farkas A., Ali H., Lucic B., Lisek K., Manganaro L. Nuclear architecture dictates HIV-1 integration site selection. Nature. 2015; 521:227–231. PubMed

Albanese A., Arosio D., Terreni M., Cereseto A.. HIV-1 pre-integration complexes selectively target decondensed chromatin in the nuclear periphery. PLoS One. 2008; 3:e2413. PubMed PMC

Lelek M., Casartelli N., Pellin D., Rizzi E., Souque P., Severgnini M., Di Serio C., Fricke T., Diaz-Griffero F., Zimmer C. et al. .. Chromatin organization at the nuclear pore favours HIV replication. Nat. Commun. 2015; 6:6483. PubMed PMC

Di Nunzio F., Fricke T., Miccio A., Valle-Casuso J.C., Perez P., Souque P., Rizzi E., Severgnini M., Mavilio F., Charneau P. et al. .. Nup153 and Nup98 Bind the HIV-1 core and contribute to the early steps of HIV-1 replication. Virology. 2013; 440:8–18. PubMed PMC

Ocwieja K.E., Brady T.L., Ronen K., Huegel A., Roth S.L., Schaller T., James L.C., Towers G.J., Young J.A.T., Chanda S.K. et al. .. HIV integration targeting: a pathway involving transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog. 2011; 7:e1001313. PubMed PMC

Pascual-Garcia P., Capelson M.. Nuclear pores in genome architecture and enhancer function. Curr. Opin. Cell Biol. 2019; 58:126–133. PubMed PMC

Pascual-Garcia P., Debo B., Aleman J.R., Talamas J.A., Lan Y., Nguyen N.H., Won K.J., Capelson M.. Metazoan nuclear pores provide a scaffold for poised genes and mediate induced enhancer-promoter contacts. Mol. Cell. 2017; 66:63–76. PubMed PMC

Ibarra A., Benner C., Tyagi S., Cool J., Hetzer M.W.. Nucleoporin-mediated regulation of cell identity genes. Genes Dev. 2016; 30:2253–2258. PubMed PMC

Liu X., Zhang Y., Chen Y., Li M., Zhou F., Li K., Cao H., Ni M., Liu Y., Gu Z. et al. .. In situ capture of chromatin interactions by biotinylated DCas9. Cell. 2017; 170:1028–1043. PubMed PMC

Price A.J., Fletcher A.J., Schaller T., Elliott T., Lee K., KewalRamani V.N., Chin J.W., Towers G.J., James L.C.. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLOS Pathog. 2012; 8:e1002896. PubMed PMC

Matreyek K.A., Yücel S.S., Li X., Engelman A.. Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog. 2013; 9:e1003693. PubMed PMC

Bhattacharya A., Alam S.L., Fricke T., Zadrozny K., Sedzicki J., Taylor A.B., Demeler B., Pornillos O., Ganser-Pornillos B.K., Diaz-Griffero F. et al. .. Structural basis of HIV-1 capsid recognition by PF74 and CPSF6. Proc. Natl. Acad. Sci. U.S.A. 2014; 111:18625–18630. PubMed PMC

Chin C.R., Perreira J.M., Savidis G., Portmann J.M., Aker A.M., Feeley E.M., Smith M.C., Brass A.L.. Direct visualization of HIV-1 replication intermediates shows that capsid and CPSF6 modulate HIV-1 intra-nuclear invasion and integration. Cell Rep. 2015; 13:1717–1731. PubMed PMC

Rasheedi S., Shun M.-C., Serrao E., Sowd G.A., Qian J., Hao C., Dasgupta T., Engelman A.N., Skowronski J.. The cleavage and polyadenylation specificity factor 6 (CPSF6) subunit of the capsid-recruited pre-messenger RNA cleavage factor I (CFIm) complex mediates HIV-1 integration into genes. J. Biol. Chem. 2016; 291:11809–11819. PubMed PMC

Sowd G.A., Serrao E., Wang H., Wang W., Fadel H.J., Poeschla E.M., Engelman A.N.. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. Proc. Natl. Acad. Sci. U.S.A. 2016; 113:E1054–E1063. PubMed PMC

Achuthan V., Perreira J.M., Sowd G.A., Puray-Chavez M., McDougall W.M., Paulucci-Holthauzen A., Wu X., Fadel H.J., Poeschla E.M., Multani A.S. et al. .. Capsid-CPSF6 interaction licenses nuclear HIV-1 trafficking to sites of viral DNA integration. Cell Host Microbe. 2018; 24:392–404. PubMed PMC

Holman A.G., Coffin J.M.. Symmetrical base preferences surrounding HIV-1, avian Sarcoma/Leukosis virus, and murine leukemia virus integration sites. Proc. Natl. Acad. Sci. U.S.A. 2005; 102:6103–6107. PubMed PMC

Wu X., Li Y., Crise B., Burgess S.M., Munroe D.J.. Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses. J. Virol. 2005; 79:5211–5214. PubMed PMC

Berry C., Hannenhalli S., Leipzig J., Bushman F.D.. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput. Biol. 2006; 2:e157. PubMed PMC

Benleulmi M.S., Matysiak J., Robert X., Miskey C., Mauro E., Lapaillerie D., Lesbats P., Chaignepain S., Henriquez D.R., Calmels C. et al. .. Modulation of the functional association between the HIV-1 intasome and the nucleosome by histone amino-terminal tails. Retrovirology. 2017; 14:54. PubMed PMC

Long Terminal Repeats of Gammaretroviruses Retain Stable Expression after Integration Retargeting

Unraveling the palindromic and nonpalindromic motifs of retroviral integration site sequences by statistical mixture models